Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01989598 · OUTCOME

Incidence of Adverse Event Reactions Reported According to CTCAE v4.0

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Adverse Events
Interval / dispersion
Not reported
Time frame
From time of treatment start until treatment completion, an average of 1 year

What was measured

Reported by type, frequency, and severity.

Groups in this outcome

Treatment (Trametinib)

Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment (Trametinib, Akt Inhibitor GSK2141795)

Patients who develop progressive disease on trametinib monotherapy or achieve less then a PR after 4 cycles of treatment will have the option to continue on trametinib with the addition of GSK2141795

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Trametinib)25
Treatment (Trametinib, Akt Inhibitor GSK2141795)12

Reported measurements

Source class 1
Values in Adverse Events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Trametinib)2Not reportedNot reportedNot reportedNot reported
Treatment (Trametinib, Akt Inhibitor GSK2141795)4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    2. group Id
      OG001
      value
      12
    units
    Participants
description
Reported by type, frequency, and severity.
groups
  1. description
    Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Trametinib)
  2. description
    Patients who develop progressive disease on trametinib monotherapy or achieve less then a PR after 4 cycles of treatment will have the option to continue on trametinib with the addition of GSK2141795
    id
    OG001
    title
    Treatment (Trametinib, Akt Inhibitor GSK2141795)
param Type
NUMBER
reporting Status
POSTED
time Frame
From time of treatment start until treatment completion, an average of 1 year
title
Incidence of Adverse Event Reactions Reported According to CTCAE v4.0
type
SECONDARY
unit Of Measure
Adverse Events

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice